Correspondence 0001193125-24-269407 from Mereo BioPharma Group plc (MREO) (CIK 0001719714) (MREO)
Mereo BioPharma Group plc (MREO) (CIK 0001719714)
Date: Dec. 3, 2024 · CIK: 0001719714 · Accession: 0001193125-24-269407
AI Filing Summary & Sentiment
File numbers found in text: 333-283439
Letter
Mereo BioPharma Group plc
One Cavendish Place, 4th Floor
London, W1G 0QF United Kingdom
December 3, 2024
Via EDGAR
Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: Mereo BioPharma Group plc
Registration Statement on Form S-3
Filed November 25, 2024
File No. 333- 283439
To whom it may concern:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Mereo BioPharma Group plc (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-283439) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on December 4, 2024 or as soon as practicable thereafter.
The Company requests that we be notified of such effectiveness by a telephone call to David S. Bakst of Mayer Brown LLP at (212) 506-2551 and that such effectiveness also be confirmed in writing.
Very truly yours,
Mereo BioPharma Group plc
Show Raw Text
CORRESP 1 filename1.htm CORRESP Mereo BioPharma Group plc One Cavendish Place, 4th Floor London, W1G 0QF United Kingdom December 3, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Mereo BioPharma Group plc Registration Statement on Form S-3 Filed November 25, 2024 File No. 333- 283439 To whom it may concern: Pursuant to Rule 461(a) under the Securities Act of 1933, as amended, Mereo BioPharma Group plc (the “Company”) hereby respectfully requests that the effective date of the Company’s Registration Statement on Form S-3 (File No. 333-283439) be accelerated by the Securities and Exchange Commission to 4:00 p.m. Washington D.C. time on December 4, 2024 or as soon as practicable thereafter. The Company requests that we be notified of such effectiveness by a telephone call to David S. Bakst of Mayer Brown LLP at (212) 506-2551 and that such effectiveness also be confirmed in writing. Very truly yours, Mereo BioPharma Group plc By: /s/ Denise Scots-Knight Denise Scots-Knight Chief Executive Officer cc: Christine Fox, Mereo BioPharma Group plc Charles Sermon, Mereo BioPharma Group plc David S. Bakst, Mayer Brown LLP